Genesys Spine Named to Inc. 5000 List of America’s Fastest-Growing Private Companies for Second Year in a Row
Austin, TX (Sept. 02, 2015) – For the second consecutive year, Genesys Spine has been recognized by INC Magazine’s annual Inc. 5000 list of the fastest-growing private companies in America.
Founded in 2009, Genesys Spine has quickly established itself in the orthopedic and neurosurgical communities with unique and innovative spinal implants.
“We are honored to be recognized as one of the fastest-growing companies in the country for a second year in a row. Our growth and success stems from our commitment to listen to the needs of the medical community and respond with products that are thoughtfully designed and engineered to meet those needs,” said Genesys Spine Principal Joshua Kaufmann.
About the Inc. 5000 list
The 2015 Inc. 5000 is the most competitive crop in the list’s history, with an aggregate revenue of $205 billion, generating 647,000 jobs over the past three years. Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at www.inc.com/inc5000.
“Only a tiny fraction of the nation’s companies have demonstrated such remarkably consistent high growth, particularly in the difficult economic environment of the past few years. This achievement truly puts you in rarefied company,” says Inc. President and Editor-In-Chief Eric Schurenberg.
The annual Inc. 5000 event honoring all the companies on the list will be held from October 21 through 23, 2014 in Orlando, Florida, Speakers include some of the greatest entrepreneurs of this and past generations.
About Genesys Spine
Founded in December of 2009, Genesys Spine was started by veterans of the spinal device industry. The founding partners have used their industry knowledge and input from existing surgeon relationships to introduce, into a mature spinal fusion market, an array of medical implants and instruments with novel characteristics. These devices, with their proprietary features, all remain within existing parameters for today’s current reimbursement codes.